Mapping of the IDDM locus Idd3 to a 0.35-cM interval containing the interleukin-2 gene

• Published in: Diabetes (New York, N.Y.) Vol. 46; no. 4; pp. 695 - 700
• Main Authors: Denny, P., Lord, C. J., Hill, N. J., Goy, J. V., Levy, E. R., Podolin, P. L., Peterson, L. B., Wicker, L. S., Todd, J. A., Lyons, P. A.
• Format: Journal Article
• Language: English
• Published: American Diabetes Association 01-04-1997
• ISSN: 0012-1797; 1939-327X; 0012-1797
• DOI: 10.2337/diabetes.46.4.695

Mapping of the IDDM locus Idd3 to a 0.35-cM interval containing the interleukin-2 gene.
P Denny ,
C J Lord ,
N J Hill ,
J V Goy ,
E R Levy ,
P L Podolin ,
L B Peterson ,
L S Wicker ,
J A Todd and
P A Lyons
Wellcome Trust Centre for Human Genetics, University of Oxford, Headington, U.K.
Abstract
Currently, 16 loci that contribute to the development of IDDM in the NOD mouse have been mapped by linkage analysis. To fine
map these loci, we used congenic mapping. Using this approach, we localized the Idd3 locus to a 0.35-cM interval on chromosome
3 containing the Il2 gene. Segregation analysis of the known variations within this interval indicated that only one variant,
a serine-to-proline substitution at position 6 of the mature interleukin-2 (IL-2) protein, consistently segregates with IDDM
in crosses between NOD and a series of nondiabetic mouse strains. These data, taken together with the immunomodulatory role
of IL-2, provide circumstantial evidence in support of the hypothesis that Idd3 is an allelic variation of the Il2 gene, or
a variant in strong linkage disequilibrium.